RLMD

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Relmada Therapeutics Inc

NASDAQ | RLMD

2.50

USD

$0.00

(

0.00%

)

At Close (As of Nov 5, 2025)

$91.94M

Market Cap

-

P/E Ratio

-2.2

EPS

$3.43

52 Week High

$0.24

52 Week Low

HEALTHCARE

Sector

RLMD Chart

Recent Chart
Price Action

RLMD Technicals

Tags:

RLMD Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -
Total Revenue $0
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$84M
Selling General And Administrative $38M
Research And Development $46M
Operating Expenses $84M
Investment Income Net -
Net Interest Income $3.5M
Interest Income $3.5M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $84M
Income Before Tax -$80M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$80M
Comprehensive Income Net Of Tax -
Ebit -$164M
Ebitda -$80M
Net Income -$80M

Revenue & Profitability

Earnings Performance

RLMD Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $46M
Total Current Assets $46M
Cash And Cash Equivalents At Carrying Value $3.9M
Cash And Short Term Investments $3.9M
Inventory -
Current Net Receivables -
Total Non Current Assets $22K
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments $41M
Other Current Assets $886K
Other Non Current Assets -
Total Liabilities $10M
Total Current Liabilities $10M
Current Accounts Payable $4.1M
Deferred Revenue -
Current Debt -
Short Term Debt -
Total Non Current Liabilities $4.5K
Capital Lease Obligations -
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total -
Other Current Liabilities $6.2M
Other Non Current Liabilities -
Total Shareholder Equity $36M
Treasury Stock -
Retained Earnings -$641M
Common Stock $30K
Common Stock Shares Outstanding $30M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$52M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization -
Capital Expenditures $0
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment $52M
Cashflow From Financing -$40K
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$80M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -
Total Revenue $0
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$84M
Selling General And Administrative $38M
Research And Development $46M
Operating Expenses $84M
Investment Income Net -
Net Interest Income $3.5M
Interest Income $3.5M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $84M
Income Before Tax -$80M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$80M
Comprehensive Income Net Of Tax -
Ebit -$164M
Ebitda -$80M
Net Income -$80M

RLMD News

RLMD Profile

Relmada Therapeutics Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company based in New York, committed to advancing innovative therapies for central nervous system (CNS) disorders and associated conditions. The company is focused on developing a robust pipeline of candidates aimed at addressing critical unmet medical needs in pain management and psychiatric disorders, utilizing cutting-edge research and technology. By prioritizing patient outcomes, Relmada is strategically positioned to become a significant contributor in the rapidly evolving CNS therapeutics market, potentially offering valuable solutions for patients and healthcare providers alike.

CHR
-45.58%
$0.07
NVVE
-8.57%
$0.19
MTC
+626.97%
$2.21
ASST
+18.80%
$1.48
RIVN
+23.36%
$15.42
LNAI
+40.28%
$1.17
NVDA
-1.75%
$195.21
BYND
-4.31%
$1.33
VHAI
0.00%
$0.00
PFE
+1.37%
$24.63
RUBI
-49.75%
$0.30
SNAP
-2.00%
$7.32
PLUG
+4.76%
$2.64
TSLA
+4.00%
$462.07
GRAB
-2.50%
$5.64
YDKG
-5.55%
$0.05
F
+2.69%
$13.13
SMX
+43.53%
$2.11
PLTR
-1.48%
$187.90
INTC
+3.64%
$38.38
DNN
-2.55%
$2.67
WTO
-0.20%
$0.04
AXDX
-61.36%
$0.03
AMD
+2.51%
$256.33
ACHR
+0.26%
$9.58
GPUS
-7.02%
$0.34
T
+0.42%
$24.54
AAL
+6.08%
$13.42
BITF
+5.72%
$4.05
CMBM
+58.82%
$3.24
KVUE
+1.62%
$16.23
ONDS
+0.67%
$6.00
CIFR
+9.77%
$24.71
RXRX
-0.80%
$4.96
SOFI
+2.38%
$30.07
SMCI
-11.11%
$42.13
TEVA
+20.23%
$24.60
BAC
-2.04%
$52.44
NFE
+10.37%
$1.49
ETHD
-14.82%
$4.48
ADAP
-15.14%
$0.05
AMCR
+2.54%
$8.07
BTG
+1.12%
$4.04
WBD
+0.70%
$22.76
IREN
+14.67%
$76.41
AAPL
+0.03%
$270.14
MARA
+3.06%
$17.13
QS
+10.49%
$17.05
VALE
+3.09%
$12.31
DVLT
-7.83%
$1.64
RIG
-0.12%
$3.89
CAN
+16.21%
$1.29
RGTI
+5.99%
$37.29
U
+18.09%
$42.36
WULF
+2.33%
$15.36
RMBL
+60.50%
$3.21
FUBO
+11.00%
$4.08
AMZN
+0.35%
$250.20
ADD
-25.47%
$0.05
NVO
+0.43%
$48.46
BURU
+0.20%
$0.29
NVTS
-14.61%
$10.46
EPWK
-6.41%
$0.07
BTBT
+3.14%
$3.28
SRM
+53.27%
$10.30
TLRY
+3.62%
$1.28
BMNR
+4.89%
$41.39
NCLH
-0.95%
$18.61
JOBY
+0.98%
$14.90
ZDAI
+13.94%
$0.52
RIOT
-1.58%
$18.97
HIMS
+3.11%
$44.12
NOK
+0.51%
$6.84
APPS
+23.14%
$7.29
CMG
+0.72%
$31.97
HTZ
-0.81%
$6.67
ALIT
-7.03%
$2.50
HOOD
+4.15%
$142.47
QBTS
+4.37%
$31.04
NGD
+2.48%
$6.80
GOOGL
-2.17%
$277.54
NIO
+2.30%
$7.32
BBD
+3.47%
$3.52
BW
+28.34%
$4.80
WLGS
-5.57%
$0.04
MU
+8.93%
$237.50
HPE
+0.59%
$23.70
AG
-7.82%
$10.65
RDHL
+2.77%
$1.11
PLTZ
+2.80%
$6.24
GGB
+5.11%
$3.59
HBAN
+0.13%
$15.29
ETWO
0.00%
$3.30
CPNG
-5.94%
$30.22
PBR
+2.62%
$12.14
ABEV
+1.46%
$2.42
ITUB
+1.55%
$7.49
PCG
+1.57%
$16.16
MSPR
-27.89%
$0.47
IONZ
-7.18%
$4.14
CHR
-45.58%
$0.07
NVVE
-8.57%
$0.19
MTC
+626.97%
$2.21
ASST
+18.80%
$1.48
RIVN
+23.36%
$15.42
LNAI
+40.28%
$1.17
NVDA
-1.75%
$195.21
BYND
-4.31%
$1.33
VHAI
0.00%
$0.00
PFE
+1.37%
$24.63
RUBI
-49.75%
$0.30
SNAP
-2.00%
$7.32
PLUG
+4.76%
$2.64
TSLA
+4.00%
$462.07
GRAB
-2.50%
$5.64
YDKG
-5.55%
$0.05
F
+2.69%
$13.13
SMX
+43.53%
$2.11
PLTR
-1.48%
$187.90
INTC
+3.64%
$38.38
DNN
-2.55%
$2.67
WTO
-0.20%
$0.04
AXDX
-61.36%
$0.03
AMD
+2.51%
$256.33
ACHR
+0.26%
$9.58
GPUS
-7.02%
$0.34
T
+0.42%
$24.54
AAL
+6.08%
$13.42
BITF
+5.72%
$4.05
CMBM
+58.82%
$3.24
KVUE
+1.62%
$16.23
ONDS
+0.67%
$6.00
CIFR
+9.77%
$24.71
RXRX
-0.80%
$4.96
SOFI
+2.38%
$30.07
SMCI
-11.11%
$42.13
TEVA
+20.23%
$24.60
BAC
-2.04%
$52.44
NFE
+10.37%
$1.49
ETHD
-14.82%
$4.48
ADAP
-15.14%
$0.05
AMCR
+2.54%
$8.07
BTG
+1.12%
$4.04
WBD
+0.70%
$22.76
IREN
+14.67%
$76.41
AAPL
+0.03%
$270.14
MARA
+3.06%
$17.13
QS
+10.49%
$17.05
VALE
+3.09%
$12.31
DVLT
-7.83%
$1.64
RIG
-0.12%
$3.89
CAN
+16.21%
$1.29
RGTI
+5.99%
$37.29
U
+18.09%
$42.36
WULF
+2.33%
$15.36
RMBL
+60.50%
$3.21
FUBO
+11.00%
$4.08
AMZN
+0.35%
$250.20
ADD
-25.47%
$0.05
NVO
+0.43%
$48.46
BURU
+0.20%
$0.29
NVTS
-14.61%
$10.46
EPWK
-6.41%
$0.07
BTBT
+3.14%
$3.28
SRM
+53.27%
$10.30
TLRY
+3.62%
$1.28
BMNR
+4.89%
$41.39
NCLH
-0.95%
$18.61
JOBY
+0.98%
$14.90
ZDAI
+13.94%
$0.52
RIOT
-1.58%
$18.97
HIMS
+3.11%
$44.12
NOK
+0.51%
$6.84
APPS
+23.14%
$7.29
CMG
+0.72%
$31.97
HTZ
-0.81%
$6.67
ALIT
-7.03%
$2.50
HOOD
+4.15%
$142.47
QBTS
+4.37%
$31.04
NGD
+2.48%
$6.80
GOOGL
-2.17%
$277.54
NIO
+2.30%
$7.32
BBD
+3.47%
$3.52
BW
+28.34%
$4.80
WLGS
-5.57%
$0.04
MU
+8.93%
$237.50
HPE
+0.59%
$23.70
AG
-7.82%
$10.65
RDHL
+2.77%
$1.11
PLTZ
+2.80%
$6.24
GGB
+5.11%
$3.59
HBAN
+0.13%
$15.29
ETWO
0.00%
$3.30
CPNG
-5.94%
$30.22
PBR
+2.62%
$12.14
ABEV
+1.46%
$2.42
ITUB
+1.55%
$7.49
PCG
+1.57%
$16.16
MSPR
-27.89%
$0.47
IONZ
-7.18%
$4.14
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.